Payment overview · 2025
General Payments
$1,874.75
97 reported records · 27 companies
Healthcare provider profile · identity verified
Robert Howard Mcconville, MD
Allopathic & Osteopathic Physicians|Family Medicine · SANFORD, NC · NPI 1104820133
Verified facts
What the public records show
CMS Open Payments records show Robert Howard Mcconville, MD received $1,874.75 in general payments during 2025 across 97 reported records.
Novo Nordisk Inc accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $383.29 | 20.4% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $186.30 | 9.9% | 11 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $159.99 | 8.5% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $145.65 | 7.8% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $113.87 | 6.1% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.34 | 5.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.64 | 3.7% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $68.73 | 3.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.99 | 3.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.83 | 2.9% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $50.01 | 2.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $49.89 | 2.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.04 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.32 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.63 | 2.4% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $37.68 | 2.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.93 | 2.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.87 | 1.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.82 | 1.7% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $29.23 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.71 | 1.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.75 | 1.3% | 1 | 2025 |
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $18.64 | 1.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.49 | 0.9% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $15.47 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.91 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.73 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,874.75 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $159.99 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $156.54 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $156.54 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $145.65 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $123.82 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.61 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $83.94 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.19 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $71.98 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $71.98 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $69.64 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $68.73 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.99 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $50.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $49.89 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $49.89 | 3 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $49.89 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.32 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.63 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $43.95 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.82 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.74 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.71 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.71 | 2 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 227 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 229 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
89 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
227 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
229 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
184 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1110 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 990 | 272 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 709 | 74 |
| Gabapentin | Gabapentin | 583 | 131 |
| Omeprazole | Omeprazole | 556 | 145 |
| Losartan Potassium | Losartan Potassium | 515 | 137 |
| Lisinopril | Lisinopril | 446 | 113 |
| Metformin Hcl | Metformin Hcl | 441 | 118 |
| Alprazolam | Alprazolam | 436 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 429 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 419 | 104 |
| Furosemide | Furosemide | 411 | 114 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 394 | 94 |
| Potassium Chloride | Potassium Chloride | 382 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 94 |
| Oxycodone Hcl | Oxycodone Hcl | 280 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 75 |
| Sertraline Hcl | Sertraline Hcl | 273 | 62 |
| Trazodone Hcl | Trazodone Hcl | 262 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 71 |
| Glipizide | Glipizide | 234 | 66 |
| Tramadol Hcl | Tramadol Hcl | 233 | 47 |
| Ozempic | Semaglutide | 229 | 40 |
| Jardiance | Empagliflozin | 227 | 46 |
| Carvedilol | Carvedilol | 220 | 58 |
| Morphine Sulfate Er | Morphine Sulfate | 217 | 23 |
| Simvastatin | Simvastatin | 213 | 60 |
| Spironolactone | Spironolactone | 206 | 62 |
| Metformin Hcl Er | Metformin Hcl | 202 | 46 |
| Clonazepam | Clonazepam | 200 | 29 |
| Eliquis | Apixaban | 184 | 33 |
| Glimepiride | Glimepiride | 177 | 45 |
| Allopurinol | Allopurinol | 176 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 168 | 30 |
| Donepezil Hcl | Donepezil Hcl | 163 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 51 |
| Montelukast Sodium | Montelukast Sodium | 157 | 43 |
| Atenolol | Atenolol | 154 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 39 |
| Lorazepam | Lorazepam | 151 | 26 |
| Mirtazapine | Mirtazapine | 148 | 32 |
| Ezetimibe | Ezetimibe | 146 | 36 |
| Celecoxib | Celecoxib | 142 | 47 |
| Finasteride | Finasteride | 140 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 30 |
| Meloxicam | Meloxicam | 136 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 36 |
| Pregabalin | Pregabalin | 128 | 21 |
| Diazepam | Diazepam | 127 | 19 |
| Fluconazole | Fluconazole | 120 | 34 |
| Promethazine Hcl | Promethazine Hcl | 118 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 24 |
| Bupropion Xl | Bupropion Hcl | 108 | 21 |
| Famotidine | Famotidine | 107 | 28 |
| Buspirone Hcl | Buspirone Hcl | 106 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 24 |
| Azithromycin | Azithromycin | 103 | 79 |
| Xarelto | Rivaroxaban | 103 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 102 | 22 |
| Prednisone | Prednisone | 99 | 38 |
| Tresiba Flextouch U-200 | Insulin Degludec | 93 | 25 |
| Glipizide Er | Glipizide | 90 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 73 |
| Myrbetriq | Mirabegron | 89 | 19 |
| Farxiga | Dapagliflozin Propanediol | 88 | 15 |
| Meclizine Hcl | Meclizine Hcl | 86 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 86 | 34 |
| Aripiprazole | Aripiprazole | 83 | 13 |
| Baclofen | Baclofen | 83 | 14 |
| Torsemide | Torsemide | 81 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 79 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 11 |
| Ondansetron Odt | Ondansetron | 78 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 14 |
| Synthroid | Levothyroxine Sodium | 76 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 74 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 69 | 14 |
| Linzess | Linaclotide | 69 | 16 |
| Alendronate Sodium | Alendronate Sodium | 68 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 68 | 23 |
| Estradiol | Estradiol | 67 | 20 |
| Ibuprofen | Ibuprofen | 67 | 15 |
| Nitroglycerin | Nitroglycerin | 64 | 22 |
| Memantine Hcl | Memantine Hcl | 63 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 17 |
| Lovastatin | Lovastatin | 61 | 13 |
| Cephalexin | Cephalexin | 60 | 40 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 14 |
| Naproxen | Naproxen | 57 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 56 | 13 |
| Colchicine | Colchicine | 52 | 21 |
| Fenofibrate | Fenofibrate | 52 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 32 |
| Methocarbamol | Methocarbamol | 47 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 33 |
| Nystatin | Nystatin | 47 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Nifedipine Er | Nifedipine | 46 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | 12 |
| Morphine Sulfate | Morphine Sulfate | 45 | suppressed |
| Primidone | Primidone | 45 | suppressed |
| Ramipril | Ramipril | 45 | 11 |
| Amoxicillin | Amoxicillin | 44 | 31 |
| Benazepril Hcl | Benazepril Hcl | 44 | 11 |
| Mupirocin | Mupirocin | 44 | 28 |
| Valacyclovir | Valacyclovir Hcl | 44 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 43 | 36 |
| Methylprednisolone | Methylprednisolone | 43 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 11 |
| Valsartan | Valsartan | 43 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 33 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 13 |
| Oxycontin | Oxycodone Hcl | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 11 |
| Chlorthalidone | Chlorthalidone | 37 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 12 |
| Metronidazole | Metronidazole | 36 | 11 |
| Topiramate | Topiramate | 36 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Gemtesa | Vibegron | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Methadone Hcl | Methadone Hcl | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 31 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Fentanyl | Fentanyl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | 12 |
| Hydrocortisone | Hydrocortisone | 26 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Felodipine Er | Felodipine | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Xtampza Er | Oxycodone Myristate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 15 |
| Risperidone | Risperidone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Euthyrox | Levothyroxine Sodium | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Norethindrone | Norethindrone | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,874.75 · 97 records | Novo Nordisk Inc | ABRYSVO, APLIGRAF, CAPVAXIVE, COMIRNATY, CREON, ETERNA, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Freelite, GARDASIL 9, GEMTESA, General - Erectile Dysfunction, HETLIOZ, IBSRELA, INSPIRE, JARDIANCE, JATENZO, KISUNLA, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, Prolastin-C Liquid, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, SLYND, TRELEGY ELLIPTA, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error